A Single Dose Study of the Pharmacodynamics, Tolerability, and Pharmacokinetics of GAL-054
Completed
- Conditions
- Breath disorders10038716
- Registration Number
- NL-OMON37672
- Lead Sponsor
- Galleon Pharmaceuticals, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 36
Inclusion Criteria
Healthy volunteer
18-45 years
Exclusion Criteria
Clinical significant abnormalities
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The pharmacodynamic effects of GAL-054 in comparison to doxapram in healthy<br /><br>subjects </p><br>
- Secondary Outcome Measures
Name Time Method <p>Tolerability and pharmacokinetics</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does GAL-054 target in breath disorders?
How does GAL-054 compare to standard-of-care treatments for respiratory conditions?
Are there specific biomarkers associated with GAL-054's pharmacodynamic effects in breath disorders?
What adverse events are commonly reported in trials of Galleon Pharmaceuticals' GAL-054?
What are the potential combination therapies involving GAL-054 for treating breath disorders?